US 11,951,203 B2
Deep wrinkle vanishing compositions
Chanda Zaveri, Rancho Palos Verdes, CA (US); and Meng Teng Lim, Island East (HK)
Filed by Chanda Zaveri, Rancho Palos Verdes, CA (US); and Meng Teng Lim, Island East (HK)
Filed on Aug. 26, 2020, as Appl. No. 17/003,652.
Prior Publication US 2022/0062143 A1, Mar. 3, 2022
Int. Cl. A61K 8/64 (2006.01); A61K 8/11 (2006.01); A61K 8/44 (2006.01); A61K 8/73 (2006.01); A61K 9/00 (2006.01); A61K 9/48 (2006.01); A61K 31/197 (2006.01); A61K 31/401 (2006.01); A61K 38/05 (2006.01); A61K 38/08 (2019.01); A61K 47/38 (2006.01); A61P 17/00 (2006.01); A61Q 19/08 (2006.01)
CPC A61K 8/64 (2013.01) [A61K 8/11 (2013.01); A61K 8/44 (2013.01); A61K 8/731 (2013.01); A61K 8/732 (2013.01); A61K 9/0053 (2013.01); A61K 9/4833 (2013.01); A61K 31/197 (2013.01); A61K 31/401 (2013.01); A61K 38/05 (2013.01); A61K 38/08 (2013.01); A61K 47/38 (2013.01); A61P 17/00 (2018.01); A61Q 19/08 (2013.01); A61K 2800/92 (2013.01)] 17 Claims
 
1. A composition comprising a first acetyl hexapeptide, a second acetyl hexapeptide, ethylhexyl cocoate, and a dipeptide having a sequence of Lys-Pro in a cosmetically or pharmaceutically acceptable carrier wherein the first acetyl hexapeptide is selected from the group consisting of acetyl hexapeptide-1, acetyl hexapeptide-3, acetyl hexapeptide-7, acetyl hexapeptide-8, acetyl hexapeptide-19, acetyl hexapeptide-20, acetyl hexapeptide-22, acetyl hexapeptide-24, acetyl hexapeptide-30, acetyl hexapeptide-31, acetyl hexapeptide-37, acetyl hexapeptide-38, acetyl hexapeptide-39, acetyl hexapeptide-46 and acetyl hexapeptide-49,
wherein the second acetyl hexapeptide is selected from the group consisting of acetyl hexapeptide-1, acetyl hexapeptide-7, acetyl hexapeptide-20, acetyl hexapeptide-22, acetyl hexapeptide-30, acetyl hexapeptide-31, acetyl hexapeptide-37, acetyl hexapeptide-38, acetyl hexapeptide-39, acetyl hexapeptide-46, acetyl hexapeptide-49 and acetyl hexapeptide-51 amide, and
wherein the first acetyl hexapeptide and the dipeptide are present in a weight ratio between 5:1 and 20:1.